|
 |
MecaserminThis page contains recent news articles, when available, and an overview of Mecasermin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.RICHMOND, VA -- December 13, 2005 -- Insmed Incorporated announced the United States Food and Drug Administration (FDA) approved Iplex(TM) (mecasermin ... DG News … response to approvable letter for iPlex.(mecasermin rinfibate... - Oct 31, 2005 However, it has not yet determined whether the approval and granting of orphan exclusivity for Tercia's Increlex (mecasermin [rDNA origin]) for severe ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Iplex.(New & Approved)(mecasermin rinfabate ) - Feb 1, 2006 The Food and Drug Administration approved Iplex (mecasermin rinfabate [rDNA origin] injection) for treatment of growth failure in children with severe, ... Free with registration - Family Practice News - AccessMyLibrary.com Mecasermin was safe, protective against hypoglycemia for pediatric … - Nov 24, 2008 Patients treated with mecasermin for use in pediatric growth failure had significant height increases and reduced incidence of hypoglycemic events, ... Endocrine Today High-dose mecasermin increases growth rates in patients with IGF-1 … - Jul 7, 2008 Mecasermin, when administered at the highest end of the recommended dose range, increased growth rates in children with primary IGF-1 deficiency without ... Endocrine Today MECASERMIN (Subcutaneous route) - mek-a-SER-min.(Drug overview) - May 1, 2007 Mecasermin is a synthetic (man-made) version of insulin-like growth factor-1 (IGF-1) hormone. IGF-1 is produced in the liver and plays an important role in ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Iplex.(New & Approved)(mecasermin rinfabate) - Jan 1, 2006 The Food and Drug Administration approved Iplex (mecasermin rinfabate [rDNA origin] injection) for treatment of growth failure in children with severe, ... Free with registration - Pediatric News - AccessMyLibrary.com mecasermin rinfabate Insmed registered, USA (GHIS). - Jan 9, 2006 Mecasermin rinfabate, a recombinant insulin-like growth factor-1 (IGF-1) coupled ... mecasermin rinfabate, somatomedin C coupled with binding protein, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Tercica, Genentech Announce Agreement for Nurtopin AQ and Increlex - Jul 13, 2007 Nutropin AQ (somatropin (rDNA origin)) and Increlex (mecasermin (rDNA origin) injection) were originally designed and formulated to be combined and ... FDA news - FDA news (subscription) FDA Accepts Tercica's Increlex(TM) New Drug Application With Priority... - May 2, 2005 The company's first product candidate, Increlex(TM) (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... RedOrbit Iplex.(New & Approved)(mecasermin rinfabate ) | Article from Family … - Feb 1, 2006 Iplex.(New & Approved)(mecasermin rinfabate ) ... find Family Practice News articles. Iplex (mecasermin rinfabate [rDNA origin] injection, Insmed Inc.) The ... Pay-Per-View - Family Practice News - HighBeam Research FDA to Review Insmed's Complete Response to Approvable Letter for … - Oct 25, 2005 The FDA has not yet determined whether the approval and granting of orphan exclusivity for mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will ... RedOrbit Iplex.(New & Approved)(mecasermin rinfabate) | Article from Pediatric... - Jan 1, 2006 Iplex.(New & Approved)(mecasermin rinfabate) ... find Pediatric News articles. Iplex (mecasermin rinfabate [rDNA origin] injection, Insmed Inc.) The Food ... Pay-Per-View - Pediatric News - HighBeam Research Insmed Submits New Drug Application -NDA- to Seek Regulatory … - Jan 3, 2005 Administration (FDA) for regulatory approval of SomatoKine(R) (mecasermin rinfabate) for the treatment of growth hormone insensitivity syndrome (GHIS). ... Free with registration - Business Wire - AccessMyLibrary.com Tercica Announces Two Presentations at the Pediatric Academic … - Apr 20, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by ... Free with registration - Business Wire - AccessMyLibrary.com Second orphan drug iPlex approved.(Wednesday, Dec. 14) - Dec 19, 2005 IPlex (mecasermin rinfabate) is a human recombinant of the naturally occurring protein complex of insulin-like growth factor 1 (IGF-1) and insulin like ... Free with registration - BioWorld Week - AccessMyLibrary.com Tercica's Increlex Pricing Provides a Significant Competitive... - Jun 5, 2006 Tercica, Inc. (Nasdaq:TRCA) today provided a price comparison of its product, Increlex(TM) (mecasermin (rDNA origin) injection) to IPLEX(TM) (mecasermin ... Genetic Engineering News - Genetic Engineering News (press release) FDA accepts for review Insmed's NDA for SomatoKine for the treatment... - Mar 10, 2005 ...for its drug candidate SomatoKine (mecasermin rinfabate), a novel once-daily IGF-I therapy for the treatment of growth hormone insensitivity syndrome. ... Pay-Per-View - Company Reports - Factiva, from Dow Jones Tercica Reports First Quarter Financial Results; Conference Call... - May 9, 2006 ...for the first quarter ended March 31, 2006 was $85000, reflecting the initial quarter of sales of Increlex(TM) (mecasermin (rDNA origin) injection). ... Genetic Engineering News - Genetic Engineering News (press release) New drugs.(Fluarix from GlaxoSmithKline PLC)(Tercica Inc. introduces ... - Sep 26, 2005 From Tercica Inc., Brisbane, Calif., a biopharmaceutical firm focusing on diseases of the endocrine system, comes newly approved Increlex (mecasermin [rDNA ... Free with registration - Drug Topics - AccessMyLibrary.com FDA issues 2005 approvals for drugs, biologic products - May 1, 2006 ...*Mecasermin (Increlex) and mecasermin rinfabate (IPLEX) for the long-term treatment of growth failure in children with severe primary growth-factor ... Free with registration - Drug Formulary Review - AccessMyLibrary.com INCRELEX Tercica submitted for approval, USA (growth disorder).( … - Mar 7, 2005 Tercica announced on 28 February 2005 that it has filed an NDA with the US FDA for injectable mecasermin (INCRELEX), a recombinant human insulin-like growth ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Insmed clarifies approvable letter on iPlex.(Public Notice) - Oct 3, 2005 The company wishes to clarify a statement in the press release issued September 27, 2005 regarding its iPlex (rhIGF-I/rhIGFBP-3; mecasermin rinfibate). ... $4.95 - Pharma Marketletter - ECNext IGF-I Deficiency; IPLEX demonstrates significant, dose-dependent … - May 29, 2006 ...multicenter clinical trial of rhIGF-I/rhIGFBP-3, or IPLEX (mecasermin rinfabate [rDNA origin] injection) administered once daily to children with severe ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Tercica moves to block Insmed growth drug in USA.(pharmaceutical … - Jun 6, 2005 US groups Tercica and Genentech say they have asked a federal court to stop Insmed from marketing its growth therapy SomatoKine (mecasermin rinfabate) ... $4.95 - Pharma Marketletter - ECNext Insmed Incorporated Announces Proposed Public Offering of Common … - Mar 6, 2006 For further information about Insmed and IPLEX(TM) (mecasermin rinfabate, rDNA origin, injection), our FDA-approved drug for the treatment of growth failure ... $4.95 - Business Wire - ECNext Increlex gains short stature approval.(Thursday, September 1) - Sep 5, 2005 Increlex (rhIGF-1, mecasermin [rDNA origin] injection), approved within a six-month priority review time frame, is the only therapy indicated to treat ... Pay-Per-View - BioWorld Week - Factiva, from Dow Jones International Approvals: Actonel, Alvesco, Increlex - Aug 27, 2007 The European Commission has approved mecasermin [rDNA origin] 10-mg/mL ... The recommended starting dose for mecasermin is 40 to 80 µg/kg twice daily by ... Medscape Insmed Submits Response to FDA Approvable Letter for iPlex. - Oct 17, 2005 ...to the Approvable Letter received from United States Food and Drug Administration (FDA) for iPlex(TM) (rhIGF-I/rhIGFBP-3) (Mecasermin rinfibate), ... $4.95 - PR Newswire - ECNext Drug Development; Response submitted to US FDA regarding … - Nov 14, 2005 ...its response to the approvable letter received from the US Food and Drug Administration (FDA) for iPlex (rhIGF-I/rhIGFBP-3) (Mecasermin rinfibate), ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Company Profile Report - Oct 11, 2008 Increlex (Mecasermin rDNA Origin)/Nutropin AQ (Somatropin rDNA Origin) Combination Products. Pituitary Gland Disorders. Acromegaly. Somatostatin Analogs ... $50.00 - Revere Reports - Revere Drug Development; Response submitted to US FDA regarding … - Nov 20, 2005 ...its response to the approvable letter received from the US Food and Drug Administration (FDA) for iPlex (rhIGF-I/rhIGFBP-3) (Mecasermin rinfibate), ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones International Approvals: CellCept and iPlex - Jul 24, 2006 Mecasermin rinfabate is a human recombinant protein complex of IGF-1 that is ... Mecasermin rinfabate has been well tolerated in clinical studies, ... Medscape Selected biotechnology, biotech-related, small-molecule and other FDA... - Feb 27, 2006 Increlex Long-term treatment for growth (mecasermin) failure in children ... Treatment of growth failure in (mecasermin rinfabate [rDNA children with ... Pay-Per-View - Chain Drug Review - HighBeam Research Neue Behandlung gegen Kleinwuchs - Dec 3, 2007 Die subkutane Injektion von Mecasermin - morgens und abends - kann das Wachstum ... Außerdem war die Wirkung von Mecasermin dosisabhängig; der beste Effekt ... Ärzte Zeitung FDA Approvals: Fluarix, Increlex, and ACTOplus met - Sep 1, 2005 Mecasermin was generally well tolerated; adverse events were mild to moderate ... The recommended starting dose for mecasermin is 40 to 80 µg/kg twice daily ... Medscape Company Profile Report - Oct 11, 2008 Increlex (Mecasermin rDNA Origin)/Nutropin AQ (Somatropin rDNA Origin) Combination Products. Pituitary Gland Disorders. Acromegaly. Somatostatin Analogs ... $50.00 - Revere - Alacra Store Drug/Medical Device Report Tercica, Inc. (TRCA) - Oct 11, 2008 Increlex (Mecasermin rDNA Origin). Crohn Disease In Children. Phase II. Endocrinology/Metabolism. Phase I/Phase II Clinical Stage Products ... $70.00 - Revere Reports - Revere Press Release: Insmed Releases Positive Results from IPLEX. - M2 … - May 1, 2007 I/rhIGFBP-3, or IPLEX(TM) (mecasermin rinfabate ... the Moscone Center in San ... based firm said Iplex (mecasermin rinfabate ... settlement to stop selling ... Pay-Per-View - M2 Presswire - HighBeam Research New growth hormone can aid short kids. - Nov 21, 2005 Mecasermin, which will be marketed as Increlex beginning in January 2006, is indicated ... The standard starting dose of mecasermin is 0.04 to 0.08 mg/kg ... $9.94 - Drug Topics - Alacra Store Tercica Announces Agreement with Genentech for Worldwide Growth … - Jul 10, 2007 About Increlex([R])(mecasermin [rDNA origin] injection): The active ingredient of Increlex([R]) is recombinant human insulin-like growth factor-1 (IGF-1). ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Tercica Presents Three Scientific Posters at the ESPE/... - Sep 23, 2005 Company's first product candidate, Increlex(TM) (mecasermin (rDNA origin) ... Application (NDA) for Increlex(TM) (mecasermin ... seeking approval to market ... Pay-Per-View - PR Newswire - HighBeam Research Neue Therapie gegen Form des Kleinwuchses - Nov 28, 2007 Sie profitieren von einer Substitution mit Mecasermin. Die neue Arznei Mecasermin (Increlex®) enthält gentechnisch hergestelltes, humanes IGF-1. ... Ärzte Zeitung IPSEN: Increlex(R) Receives Marketing Authorisation in the European … - Aug 9, 2007 Increlex([R]) should not be used in people who may be hypersensitive (allergic) to mecasermin or any of the other ingredients. It should also not be used in ... Free with registration - Business Wire - AccessMyLibrary.com Drug/Medical Device Report Tercica, Inc. (TRCA) - Oct 11, 2008 Biopharmaceuticals. Endocrinology/Metabolism. Phase I/Phase II Clinical Stage Products. Increlex (Mecasermin rDNA. Origin)/Nutropin AQ (Somatropin rDNA. $70.00 - Revere - Alacra Store Press Release: Insmed Releases Study On Growth Drug. - M2 Presswire |... - Dec 15, 2006 1 response to the Approvable Letter for iPlex(TM) (mecasermin rinfibate (rDNA origin ... to complete its 60-day review of the iPlex New Drug Application ... Pay-Per-View - M2 Presswire - HighBeam Research Competitors by Product Report - Oct 11, 2008 Products:. Increlex (Mecasermin rDNA Origin)/Nutropin AQ (Somatropin rDNA Origin) Combination Products. Abbott Laboratories (ABT) Products: ... $75.00 - Revere Reports - Revere Insmed Withdraws Its Marketing Authorisation Application For IPLEX - Mar 26, 2007 Mecasermin rinfabate was designated as an orphan medicinal product for the treatment of these conditions on 20 June 2006. ... Medical News Today - Medical News Today (press release) IPSEN expands its short-stature product portfolio - Sep 18, 2007 Ipsen Ltd, the UK subsidiary of the Ipsen Group, has expanded its short-stature treatment portfolio with the launch this week of Increlex® (mecasermin), ... Healthcare Republic - Healthcare Republic Tercica Launches Increlex In The US, Long-Term Treatment Of Growth … - Jan 6, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by ... Medical News Today - Medical News Today (press release) Tercica Signs International Distribution Agreements for Increlex;... - Jun 14, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... Genetic Engineering News - Genetic Engineering News (press release) Tercica Presents Updated Increlex Long-Term Treatment Data at the … - May 11, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... Genetic Engineering News - Genetic Engineering News (press release) FDA to Review Insmed's Complete Response to Approvable Letter for … - Aug 23, 2005 The FDA has not yet determined whether the approval and granting of orphan exclusivity for mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will ... businesswire.com Tercica Announces Poster Presentations at the 45th Annual Meeting of ... - Jul 3, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... Genetic Engineering News - Genetic Engineering News (press release) Ipsen wins positive EU panel view on drug Increlex - May 25, 2007 The Committee for Medicinal Products for Human Use on Friday recommended marketing clearance for Increlex, chemically known as mecasermin, in a 10 mg/ml ... Reuters Insmed, Inc. US FDA to review response to approvable letter for iPlex - Nov 23, 2005 The FDA has not yet determined whether the approval and granting of orphan exclusivity for mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Tercica Appoints Chris E. Rivera Senior Vice President, Commercial … - Apr 14, 2005 Tercica's first product candidate, Increlex(TM) (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... $4.95 - PR Newswire - ECNext Severe Primary IGF-1 Deficiency; US FDA to review response to … - Nov 25, 2005 The FDA has not yet determined whether the approval and granting of orphan exclusivity for mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Investor Group acquires Medical Solutions FZ LLC from Medical... - Nov 27, 2006 Increlex (mecasermin) is an aqueous solution for injection containing human insulin…mecasermi n) ... Increlex (mecasermin) ## mg/ml solution for injection. ... Pay-Per-View - deals - Alacra Store Severe Primary IGF-1 Deficiency; US FDA to review response to … - Nov 27, 2005 The FDA has not yet determined whether the approval and granting of orphan exclusivity for mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Press Release: IPLEX(TM) Demonstrates Significant, Dose-Dependent … - May 1, 2006 ...or IPLEX(TM) (mecasermin rinfabate [rDNA origin] injection) administered ... says that the European Commission has granted Increlex (mecasermin [rDNA ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Tercica Files Preliminary Injunction Against Insmed... - May 31, 2005 The Company's first product candidate, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... Pay-Per-View - PR Newswire - HighBeam Research Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press … - Sep 29, 2005 ...recent approval and granting of orphan exclusivity for Mecasermin (rDNA origin) for Severe Primary IGF-1 deficiency will block the approval of iPlex. ... $4.95 - Business Wire - ECNext Press Release: Tercica Presents Two Pharmacokinetic Studies in an... - Jun 7, 2005 Preliminary observations of this effect were included in the company's New Drug Application (NDA) for Increlex(TM) (mecasermin [rDNA origin] ... ... Pay-Per-View - PR Newswire - HighBeam Research Factiva Search - Jun 5, 2006 ...mecasermin rinfabate Insmed marketed, USA (GHIS).(Brief article) ... Insmed announced on 25 May 2006 that it has launched mecasermin rinfabate (IPLEX) in ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Tercica Reports First Quarter 2005 Financial Results. - May 5, 2005 The Company's first product candidate, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... $4.95 - PR Newswire - ECNext Factiva Search - Oct 31, 2005 FDA approves Mecasermin for dwarfism in children. 31 October, 2005 Die Pharmazeutische Industrie. Tercica Inc received the approval for Increlex ... Pay-Per-View - Die Pharmazeutische Industrie - Factiva, from Dow Jones Insmed files Citizen Petition to block Tercica's Increlex.(markets)(Br... - Aug 22, 2005 Insmed has a comparable product in development, SomatoKine (mecasermin rinfabate), and the two firms are competing for the marketing exclusivity afforded by ... $4.95 - Pharma Marketletter - ECNext Press Release: Market Gainer Updates Shareholders Of Insmed … - May 25, 2006 Insmed Incorporated (NASDAQ:INSM) announced the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). IPLEX was approved as an orphan ... Pay-Per-View - M2 Presswire - HighBeam Research Tercica Files Preliminary Injunction Against Insmed and Celtrix. - May 31, 2005 The Company's first product candidate, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... $4.95 - PR Newswire - ECNext TEXT-EU agency details decisions on new drugs - May 25, 2007 Increlex (mecasermin), from Tercica Europe Ltd, for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like ... Reuters Highlights of rising and falling US stocks - MarketWatch - Sep 29, 2005 Insmed tumbled 12.6% after the company clarified that the Food and Drug Administration has not yet determined whether granting the mecasermin drug orphan ... MarketWatch ì?¸ìŠ¤ë©”드社 개발 IGF-1 대체 ìš”ë²•ì œâ€¦'ì?¸í?¬ë¦¬ë ‰ìŠ¤'와 ê²½ìŸ? - Dec 15, 2005 ...ë¯¸êµ ë²„ì§€ë‹ˆì•„ì£¼ 리치몬드ì—? 소재한 ìƒ?명공학사 ì?¸ìŠ¤ë©”ë“œ(Insmed)는 지난 12ì?¼ ì?´ëŸ¬í•œ 1ì?¼ 1회 ì£¼ì‚¬ì œ 'ì?´í”Œë ‰ìŠ¤'(Iplex, mecasermin rinfabate)ê°€ 중ì¦? ì›?발성 ì?¸ìŠ?린 ... 디지틀보사 Tercica Reports Fourth Quarter and Year-End 2007 Financial Results - Feb 27, 2008 In August 2007, the European Commission granted marketing authorization for Increlex® (mecasermin) 10 mg/ml solution for injection. ... Lifescience-online Tercica Announces Results from Increlex(R) IGFD Patient Registry and ... - Jun 16, 2008 Increlex(R) (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency. ... Genetic Engineering News - Genetic Engineering News (press release) New IGF drug stirs competition in growth factor segment - Sep 30, 2005 On August 31, the US Food and Drug Administration (FDA) approved Tercica's Increlex (mecasermin) recombinant human IGF-1 as a long-term treatment for ... Nature.com Researchers seek to focus attention upon the distributors of human … - Jun 17, 2008 Enhancing the law should include the addition of sermorlin (growth hormone releasing hormone [GHRH]) and mecasermin (insulin-like growth factor I [IGF-1]) ... Eureka! Science News Companion Diagnostics Gaining Ground, But Slowly - Jun 16, 2008 Among Ipsen's products is Increlex (mecasermin), a recombinant DNA-derived insulin-like growth factor-1 partnered with Tercica Inc., of Brisbane, Calif., ... BioWorld Online - BioWorld Online StreetInsider.com Pre-Open Movers 07/11 - Jul 11, 2007 ...(rDNA origin)) and Tercica\'s recombinant insulin-like growth factor-1 Increlex (mecasermin (rDNA origin) injection) for the treatment of short stature, ... StreetInsider.com - StreetInsider.com (subscription) Tercica Initiates Phase II Clinical Trial with Next-Generation Growth... - Jan 22, 2008 Nutropin AQ(R) (somatropin (rDNA origin)) and Tercica's recombinant insulin-like growth factor-1 Increlex(R) (mecasermin (rDNA origin) injection). ... Genetic Engineering News - Genetic Engineering News (press release) Are you getting a sinking feeling? - Oct 26, 2005 Joseph Dillman, a Libertyville reader wants you to know that Tercica acquired the manufacturing rights for Mecasermin. News Headline: "Brazilian couple's ... $2.95 - Chicago Sun-Times - NewsBank Increlex First To FDA Finish Line In Gaining Short Stature Approval - Sep 1, 2005 Increlex (rhIGF-1, mecasermin [rDNA origin] injection), approved within a six-month priority review time frame, is the only therapy indicated to treat ... BioWorld Online - BioWorld Online Tercica Announces Results From Increlex(R) IGFD Patient Registry And ... - Jun 19, 2008 Increlex® (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency. ... Medical News Today - Medical News Today (press release) IGF-1 Case Settled At Last; Favors Tercica Over Insmed - Mar 8, 2007 The FDA approved Tercica's rhIGF-1 Increlex (mecasermin) in the summer of 2005 for long-term treatment of severe primary IGFD, and Tercica launched the ... BioWorld Online - BioWorld Online Tercica Announces Results from Increlex(R) Phase IIIb Study … - Nov 12, 2008 ...a wholly-owned subsidiary of Ipsen (Euronext: IPN) today announced Phase IIIb clinical trial results demonstrating that Increlex ® (mecasermin (rDNA ... Genetic Engineering News - Genetic Engineering News (press release) Tercica Completes Enrollment of Clinical Trial MS301 Evaluating … - Jul 19, 2007 ...a study evaluating the efficacy and safety of the current formulation of Increlex(R) (mecasermin (rDNA origin) injection) administered in children with ... Genetic Engineering News - Genetic Engineering News (press release) Tercica to Present at Pacific Growth Equities 2006 Life Sciences... - Jun 7, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by ... Genetic Engineering News - Genetic Engineering News (press release) INSMED Announces IPLEX(TM) Availability Nationwide for Children With ... - May 25, 2006 Insmed Incorporated (NASDAQ:INSM) announced today the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). ... RedOrbit Tercica presents pharmacokinetic and safety data from several studies... - Jun 6, 2005 The company's first product candidate, Increlex TM (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... eurekalert.org FDA Approves Tercica's Increlex for Short Stature Caused by Severe … - Aug 31, 2005 BRISBANE, CA -- August 31, 2005 -- Tercica, Inc. announced today that the US Food and Drug Administration (FDA) has approved Increlex(TM) (mecasermin [rDNA ... DG News BellwetherReport.com Issues Morning Alert for Insmed Inc. - May 25, 2006 Insmed Incorporated announced today the nationwide availability of IPLEX(TM) (mecasermin rinfabate (rDNA origin). IPLEX was approved as an orphan drug by ... Free with registration - M2 Presswire - AccessMyLibrary.com Insmed Provides Update on IPLEX(TM) Launch; Company Shares Details … - Jun 9, 2006 Insmed, Inc (NASDAQ: INSM) today provided an update on the launch of IPLEX (mecasermin rinfabate (rDNA origin) injection) and the Company's payer ... Free with registration - Business Wire - AccessMyLibrary.com European Medicines Agency Validates Insmed's Regulatory Application … - Jul 5, 2006 Medicines Agency (EMEA) has validated its application to market IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection), in the European Union (EU). ... Medical News Today - Medical News Today (press release) European Commission Grants Orphan Medicinal Product Designation to … - May 31, 2006 BRISBANE, CA -- May 31, 2006 -- Tercica, Inc. today announced that the European Commission has granted Increlex(TM) (mecasermin (rDNA origin) injection) ... DG News Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary... - Sep 29, 2005 Insmed Incorporated (NASDAQ: INSM) provided an update on its ongoing pivotal clinical trial of iPlex(TM) (rhIGF-1/rhIGFBP-3) (Mecasermin rinfibate) for the ... RedOrbit Tercica to Hold Conference Call to Discuss Worldwide Strategic … - Jul 18, 2006 The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), ... Free with registration - Business Wire - AccessMyLibrary.com Insmed Announces Additional Information in Compliance with NASDAQ … - Mar 22, 2006 For further information about Insmed and IPLEX (mecasermin rinfabate(rDNA origin) injection), our FDA-approved drug for the treatment of growth failure in ... Free with registration - Business Wire - AccessMyLibrary.com SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at... - Sep 19, 2005 Insmed Incorporated (NASDAQ: INSM) today announced that data from the Company's New Drug Application for Somatokine (rhIGF-I/rhIGFBP-3) (mecasermin ... RedOrbit Insmed Presents Positive IPLEX(TM) Data At ENDO 2006. - Jun 27, 2006 Insmed, Inc. (NASDAQ: INSM) today announced new study results that show that IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection) is effective in ... Free with registration - Business Wire - AccessMyLibrary.com Insmed Reports Detailed Positive Results From Its Pivotal Clinical... - May 31, 2005 Insmed Incorporated (NASDAQ: INSM) announces updated results for the Company's pivotal Phase III clinical trial evaluating SomatoKine(R) (mecasermin ... RedOrbit |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |